ALK Gene Rearrangements As A Therapeutic Target in Non-small Cell Lung Cancer

Karen Reckamp, MD, provides an overview of ALK gene rearrangements and their clinical significance in patients with advanced NSCLC.

Jyoti Patel, MD, and Karen Reckamp, MD, discuss strategies for identifying ALK rearrangements in patients with advanced NSCLC and which patients should be tested for these alterations.

Jyoti Patel, MD, elucidates the mechanism of action of various ALK targeting agents in NSCLC and the optimal formulations and dosing strategies in patients with advanced NSCLC.

Karen Reckamp, MD, and Jyoti Patel, MD, review currently available frontline treatment options for ALK+ advanced NSCLC and discuss updated efficacy and safety data from key clinical trials of these agents in advanced NSCLC.

Jyoti Patel, MD, and Karen Reckamp, MD, share insights on factors to consider when selecting the appropriate therapy for patients with ALK+ advanced NSCLC.

Karen Reckamp, MD, and Jyoti Patel, MD, outline their treatment approaches for patients with ALK+ NSCLC who progress on frontline TKIs.

Jyoti Patel, MD, and Karen Reckamp, MD, evaluate the treatment of patients with ALK+ advanced NSCLC with brain metastases.

Karen Reckamp, MD, and Jyoti Patel, MD, discuss unmet needs, novel treatment strategies, and future perspectives for patients with ALK+ advanced NSCLC.